罗氟司特治疗稳定期COPD疗效与安全性的系统评价
发布时间：2019-02-14 10:33
【摘要】：目的系统评价罗氟司特在治疗慢性阻塞性肺疾病(COPD)的疗效及安全性,以便于对临床治疗提供参考。方法计算机检索PubMed、Web of Scinece、Springer link、Ovid、clinicaltrials.gov、CBM、Wangfang Date、CJFD等数据库,制定纳入及排除的试验标准,纳入比较罗氟司特和安慰剂治疗COPD的随机对照试验(RCT),检索时间为建库至2014年12月,提取相关数据,并评估纳入试验的方法学质量后,采用Rev Man 5.3软件进行统计分析。结果共纳入了10个RCT。Meta分析结果显示:(1)罗氟司特能显著改善COPD患者的pre-FEV1[WMD=57.04ml,95%CI(45.22,68.85),P0.00001],同时改善其他肺功能指标;(2)罗氟司特可以明显减少COPD急性加重率[RR=0.84,95%CI(0.75,0.94),P=0.002],改善COPD患者TDI评分[WMD=0.23,95%CI[0.04,0.42],P=0.02],但不能改善SGRQ评分[WMD=-0.48,95%CI(-2.39,1.43),P=0.63];(3)罗氟司特组较安慰剂组的不良事件发生率增加,表现为腹泻、恶心、头痛、体重减轻等。结论罗氟司特治疗COPD患者可以显著改善患者的肺功能、减少COPD急性加重率,具有较好的安全性。
[Abstract]:Objective to evaluate the efficacy and safety of roflostast in the treatment of chronic obstructive pulmonary disease (COPD). Methods PubMed,Web of Scinece,Springer link,Ovid,clinicaltrials.gov,CBM,Wangfang Date,CJFD and other databases were searched, and the criteria for inclusion and exclusion were established, and the randomized controlled trial (RCT), was used to compare roflustast with placebo in COPD. The retrieval time is from the construction of the database to December 2014. After extracting the relevant data and evaluating the quality of the methodology included in the experiment, the statistical analysis is carried out with Rev Man 5.3 software. Results the results of 10 RCT.Meta analysis showed that: (1) roflustrast could significantly improve pre-FEV1 [WMD=57.04ml,95%CI (45.2248.85), P0.00001] in patients with COPD, and improve other pulmonary function indexes at the same time; (2) roflustrast could significantly reduce the acute exacerbation rate of COPD [RR=0.84,95%CI (0.75-0.94), P0. 002], and improve the TDI score of COPD patients [WMD=0.23,95%CI [0.04 卤0.42], P0. 02]. But the SGRQ score was not improved [WMD=-0.48,95%CI (-2.39 卤1.43), P < 0.63]; (3) the incidence of adverse events in roflustast group was higher than that in placebo group, including diarrhea, nausea, headache, weight loss and so on. Conclusion roflostatin can significantly improve the pulmonary function and reduce the acute exacerbation rate of COPD in patients with COPD.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R563.9
本文编号：2422127
[Abstract]:Objective to evaluate the efficacy and safety of roflostast in the treatment of chronic obstructive pulmonary disease (COPD). Methods PubMed,Web of Scinece,Springer link,Ovid,clinicaltrials.gov,CBM,Wangfang Date,CJFD and other databases were searched, and the criteria for inclusion and exclusion were established, and the randomized controlled trial (RCT), was used to compare roflustast with placebo in COPD. The retrieval time is from the construction of the database to December 2014. After extracting the relevant data and evaluating the quality of the methodology included in the experiment, the statistical analysis is carried out with Rev Man 5.3 software. Results the results of 10 RCT.Meta analysis showed that: (1) roflustrast could significantly improve pre-FEV1 [WMD=57.04ml,95%CI (45.2248.85), P0.00001] in patients with COPD, and improve other pulmonary function indexes at the same time; (2) roflustrast could significantly reduce the acute exacerbation rate of COPD [RR=0.84,95%CI (0.75-0.94), P0. 002], and improve the TDI score of COPD patients [WMD=0.23,95%CI [0.04 卤0.42], P0. 02]. But the SGRQ score was not improved [WMD=-0.48,95%CI (-2.39 卤1.43), P < 0.63]; (3) the incidence of adverse events in roflustast group was higher than that in placebo group, including diarrhea, nausea, headache, weight loss and so on. Conclusion roflostatin can significantly improve the pulmonary function and reduce the acute exacerbation rate of COPD in patients with COPD.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R563.9
【参考文献】
相关期刊论文 前1条
1 冯桂山;宋宁;段争;吴雅莉;;罗氟司特治疗慢性阻塞性肺疾病药理作用的临床前研究现况[J];临床荟萃;2011年04期
，本文编号：2422127
本文链接：https://www.wllwen.com/yixuelunwen/huxijib/2422127.html
最近更新
教材专著
